III期ReSPECT研究已完成入组，该研究旨在预防接受异基因血液和骨髓移植的成人患者发生真菌感染 ReSPECT研究的主要结果预计将于2026年中期公布 英国剑桥--(BUSINESS WIRE)--(美国商业资讯)-- Mundipharma今日宣布，正在进行的全球III期ReSPECT试验已完成患者招募，该试验 ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...

Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram ...

Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...

(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patientsFavorable safety and PK profile, with encouraging activity, demonstrate a ...

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...

During the ongoing government shutdown, ClinicalTrials.gov, the nation’s central registry for medical research and clinical ...

Roseman University of Health Sciences and PDS Health® celebrated the dedication and ribbon-cutting of the new Thorne Clinic ...

Introduction: The Power of PurposeWhen people think about careers in science or healthcare, their minds often jump straight ...

The Estée Lauder Companies Inc. (NYSE:EL), today celebrated the sixtieth anniversary of its Manufacturing & Fulfillment ...

Amalgam’s Scalable Digital Platform Powers the Mobile App for Biolinq Shine™, an FDA De Novo–Cleared, Needle-Free Glucose ...